Synergistic antitumor activity of regorafenib and lapatinib in preclinical models of human colorectal cancer. (1st February 2017)

• Record Type: Journal Article
• Authors: Zhang, Wen-Ji; Li, Yong; Wei, Meng-Ning; Chen, Yao; Qiu, Jian-Ge; Jiang, Qi-Wei; Yang, Yang; Zheng, Di-Wei; Qin, Wu-Ming; Huang, Jia-Rong; Wang, Kun; Zhang, Wen-Juan; Wang, Yi-Jun; Yang, Dong-Hua; Chen, Zhe-Sheng; Shi, Zhi
• Is Part Of: Cancer letters. Volume 386(2017)
• Page Start: 100
• Page End: 109
• Publication Date: 2017-02-01
• Subjects: Regorafenib -- Lapatinib -- Targeted therapy -- Combination chemotherapy -- Colorectal cancer; Cancer -- Periodicals; Neoplasms -- Periodicals; Cancer -- Périodiques; Electronic journals; 616.994
• DOI: 10.1016/j.canlet.2016.11.011
• Languages: English
• ISSNs: 0304-3835

Abstract

Abstract: Regorafenib significantly prolongs overall survival in patients with metastatic colorectal cancer (mCRC), but the overall clinical efficacy of regorafenib remains quite limited. Combination chemotherapy is a potentially promising approach to enhance anticancer activity, overcome drug resistance, and improve disease-free and overall survival. The current study investigates the antitumor activity of regorafenib in combination with lapatinib in preclinical models of human CRC. Our results show improved antitumor efficacy when regorafenib is combined with lapatinib both in vitro and in vivo . Furthermore, pharmacokinetic analyses revealed that regorafenib and lapatinib do not influence on each plasma concentration. The finding that regorafenib in combination with lapatinib have synergistic activity warrants further clinical investigation of this beneficial combination as a potential treatment strategy for CRC patients. Highlights: Regorafenib and lapatinib have synergistic anticancer effects on human CRC in vitro and in vivo . Regorafenib and lapatinib do not influence on each plasma concentration. The synergistic activity warrants further clinical investigation of the combination as a potential treatment for CRC patients.